These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 9692654)

  • 1. Effect of plasma TNF-alpha on filgrastim-stimulated hematopoiesis in mice and humans.
    Petros WP; Rabinowitz J; Gibbs JP; Hall IH; Stuart AR; Peters WP
    Pharmacotherapy; 1998; 18(4):816-23. PubMed ID: 9692654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of granulocyte-macrophage colony-stimulating factor on the immune response of circulating monocytes after severe trauma.
    Flohé S; Lendemans S; Selbach C; Waydhas C; Ackermann M; Schade FU; Kreuzfelder E
    Crit Care Med; 2003 Oct; 31(10):2462-9. PubMed ID: 14530752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions.
    Hartung T; Doecke WD; Bundschuh D; Foote MA; Gantner F; Hermann C; Lenz A; Milwee S; Rich B; Simon B; Volk HD; von Aulock S; Wendel A
    Clin Pharmacol Ther; 1999 Oct; 66(4):415-24. PubMed ID: 10546926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells.
    Basser RL; To LB; Begley CG; Juttner CA; Maher DW; Szer J; Cebon J; Collins JP; Russell I; Olver I
    Clin Cancer Res; 1995 Jul; 1(7):715-21. PubMed ID: 9816037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients.
    Janik JE; Miller LL; Kopp WC; Taub DD; Dawson H; Stevens D; Kostboth P; Curti BD; Conlon KC; Dunn BK; Donegan SE; Ullrich R; Alvord WG; Gause BL; Longo DL
    Clin Immunol; 1999 Dec; 93(3):209-21. PubMed ID: 10600331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose and dose rate effects of whole-body gamma-irradiation: II. Hematological variables and cytokines.
    Gridley DS; Pecaut MJ; Miller GM; Moyers MF; Nelson GA
    In Vivo; 2001; 15(3):209-16. PubMed ID: 11491015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
    Skarlos DV; Timotheadou E; Galani E; Samantas E; Grimani I; Lianos E; Aravantinos G; Xanthakis I; Pentheroudakis G; Pectasides D; Fountzilas G
    Oncology; 2009; 77(2):107-12. PubMed ID: 19622901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
    Venturini M; Del Mastro L; Aitini E; Baldini E; Caroti C; Contu A; Testore F; Brema F; Pronzato P; Cavazzini G; Sertoli MR; Canavese G; Rosso R; Bruzzi P
    J Natl Cancer Inst; 2005 Dec; 97(23):1724-33. PubMed ID: 16333028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necrosis factor production by rat Kupffer cells-regulation by lipopolysaccharide, macrophage activating factor and prostaglandin E2.
    Tanaka M; Ishibashi H; Hirata Y; Miki K; Kudo J; Niho Y
    J Clin Lab Immunol; 1996; 48(1):17-31. PubMed ID: 10332631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does granulocyte colony-stimulating factor ameliorate the proinflammatory response in human meningococcal septic shock?
    Rojahn A; Brusletto B; Øvstebø R; Haug KB; Kierulf P; Brandtzaeg P
    Crit Care Med; 2008 Sep; 36(9):2583-9. PubMed ID: 18679115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of molgramostim, filgrastim and lenograstim in the treatment of myelokathexis.
    Cernelc P; Andoljsek D; Mlakar U; Pretnar J; Modic M; Zupan IP; Zver S
    Pflugers Arch; 2000; 440(5 Suppl):R81-2. PubMed ID: 11005621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative gene expression of cytokines in peripheral blood leukocytes stimulated in vitro: modulation by the anti-tumor nerosis factor-alpha antibody infliximab and comparison with the mucosal cytokine expression in patients with ulcerative colitis.
    Moriconi F; Raddatz D; Ho NA; Yeruva S; Dudas J; Ramadori G
    Transl Res; 2007 Oct; 150(4):223-32. PubMed ID: 17900510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
    Weiser MA; O'Brien S; Thomas DA; Pierce SA; Lam TP; Kantarjian HM
    Cancer; 2002 Jan; 94(2):285-91. PubMed ID: 11900213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model.
    Rivera E; Erder MH; Moore TD; Shiftan TL; Knight CA; Fridman M; Brannan C; Danel-Moore L; Hortobagyi GN;
    Cancer; 2003 Jul; 98(2):222-8. PubMed ID: 12872339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.
    Madhusudan S; Foster M; Muthuramalingam SR; Braybrooke JP; Wilner S; Kaur K; Han C; Hoare S; Balkwill F; Talbot DC; Ganesan TS; Harris AL
    Clin Cancer Res; 2004 Oct; 10(19):6528-34. PubMed ID: 15475440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness of Leukostim, a Russian preparation of granulocyte colony-stimulating factor, in the treatment of chemotherapy-induced neutropenia in patients with malignant tumors].
    Korman DB; Boronovskaia LE; Maslova IA; Andreeva EV; Seregina GV
    Vopr Onkol; 2008; 54(5):639-42. PubMed ID: 19069482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
    Weycker D; Hackett J; Edelsberg JS; Oster G; Glass AG
    Ann Pharmacother; 2006 Mar; 40(3):402-7. PubMed ID: 16492793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of cytokines and colony-stimulating factors on passive polymorphonuclear leukocyte deformability in vitro.
    Skoutelis AT; Kaleridis VE; Gogos CA; Athanassiou GM; Missirlis YF; Bassaris HP
    Cytokine; 2000 Nov; 12(11):1737-40. PubMed ID: 11052829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
    Crippa L; Gasparri A; Sacchi A; Ferrero E; Curnis F; Corti A
    Cancer Res; 2008 Feb; 68(4):1154-61. PubMed ID: 18281491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.